Cymbio Pharma Private Limited - Due diligence report

A 360° intelligence report on Cymbio Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and d…

1998-09-14 Bangalore, Karnataka Active Unlisted Active Compliant
Share
Connect MCP
CP Cymbio Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Cymbio Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
71/100
Trust Score
Moderate

Cymbio Pharma Private Limited is assessed as Moderate with a Trust Score of 71/100. Cymbio Pharma Private Limited is an active private limited indian non-government company incorporated in 1998, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.

Report generated on 02 Oct 2026 from the latest processed filings. Cymbio Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Weak

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
71/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
38/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
30/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
65/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 30/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 38%).
  • Profitable - internal accruals available.

Charges position: 3 open (30.29 cr) · 2 satisfied (4.10 cr).

Banking relationships (from registered charges)
LenderChargesAmount
State Bank Of India3 48.0 cr
Others2 48.0 cr
Compliance Score: 38/100 Caution Indicated
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
  • Flagged by authority: EPFO.
  • Litigation present in 1 court forum(s).
  • 1 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SUDARSHAN KARLE 01234567 Director 01/04/2018 6 yrs Approved
MAHENDRA KARLE 01234567 Director 01/04/2018 6 yrs Approved
FIONA KARLE 01234567 Director 01/04/2018 6 yrs Approved
KYUNG SEON CHO 01234567 Director 01/04/2018 6 yrs Approved
  • 4 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 2 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 65 · Distress 80
Growth signals & trust indicators
Latest year revenue grew 1.42.
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 28+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
Compliance score is weak (38/100).
3 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence60/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment46/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 30.29 cr already registered.
  • Compliance gaps should be priced into terms.
Investor view70/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
04 Feb 2025
Charge created
State Bank Of India - 20.00 cr
30 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
31 Mar 2021
Charge created
Others - 35.00 Lakh
04 Jul 2019
Charge satisfied
State Bank Of India
31 Mar 2018
Share transfer (FY 2018)
5400.00000000 shares to SUDARSHAN KARLE
Share transfer (FY 2018)
5400.00000000 shares to MAHENDRA KARLE
06 May 2016
Director ceased
AMRITA AJITH
23 Jul 2014
Charge satisfied
State Bank Of India
26 Jun 2014
Charge created
Others - 9.94 cr
31 Jan 2009
Securities allotted
1000000.00 Equity Shares - 1.00 cr raised
24 May 2004
Director appointed
FIONA KARLE (Director)
Director appointed
KYUNG SEON CHO (Director)
24 May 2003
Director appointed
SUDARSHAN KARLE (Director)
Director appointed
MAHENDRA KARLE (Director)
10

Key Observations

Auto-generated from the data above
Revenue declined 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
United Chemicals And Industries Private Limited U02411KA1994PTC016646 Bangalore, Karnataka, India
Ganeshkrupa Chemicals And Fertilisers Private Limited U24120MH2004PTC148831 Mumbai, Maharashtra, India
Vsvr Chems Private Limited U24114TZ2011PTC016668 Palladam, Tamil Nadu, India
Flo-Rite Baby Products Private Limited U74999MH2006PTC163577 Mumbai, Maharashtra, India
Bhilai Chemical Pvt Ltd U23209WB1995PTC072359 Kolkata, West Bengal, India
Bi-Ki Dyes And Chemicals Private Limited U24299GJ2004PTC044525 Ahmedabad, Gujarat, India
Mahavir Dischem Private Limited U24100RJ2016PTC049355 Jaipur, Rajasthan, India
Vishwadutt Minerals Pvt Ltd U17113MH1975PTC335437 Nagpur, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Cymbio Pharma Private Limited before audits and certifications: compliance score 38/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Cymbio Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 30/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 65/100, margin trends, ownership structure and peer set for Cymbio Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 71/100, distress signals and MSME payment-delay disclosures - know whether Cymbio Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Cymbio Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Cymbio Pharma Private Limited an active company?

Cymbio Pharma Private Limited has MCA status “Active” with a compliance score of 38/100 (Caution Indicated).

Is Cymbio Pharma Private Limited financially healthy?

Cymbio Pharma Private Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Cymbio Pharma Private Limited?

Its overall Trust Score is 71/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Cymbio Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 4 active director(s) are on record.

Does Cymbio Pharma Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.

Is Cymbio Pharma Private Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 38/100 (Caution Indicated).

Is it risky to lend to Cymbio Pharma Private Limited?

Its Credit Risk Score is 30/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.